Tirzepatide

Tirzepatide C화학적 특성, 용도, 생산

개요

Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

용도

Tirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes.  Controlling high blood sugar helps prevent kidney damage, blindness,  nerve problems, loss of limbs, and sexual function problems.

상품명

brand name: Mounjaro

Mechanism of action

It works to stimulate first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.  Tirzepatide was also shown to delay gastric emptying, lower fasting and  postprandial glucose concentration, decrease food intake, 4 and reduce body weight in patients with type 2 diabetes.

부작용

The overall safety and tolerability profile of tirzepatide was similar to other incretin-based therapies that have been approved for the treatment of obesity. This said, reported side effects were considerable, especially as dosage levels increased. The most common adverse events were nausea (~30%), diarrhea (~20%), constipation (~15%) and vomiting (~10%).
If tirzepatide gets approved as a both a blood glucose control and anti-obesity agent, it could become a blockbuster drug. However, this isn’t a sure thing. It will have to overcome pricing and reimbursement obstacles, which have plagued similar treatments.

Clinical claims and research

Tirzepatide (Eli Lilly), a novel, once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 RA combination drug, has been developed to treat patients with T2DM. The manufacturer (Eli Lilly) announced the submission of a biologics license application with priority review to the FDA for T2DM on October 27, 2021, with a decision expected in mid-2022.

Research

Tirzepatide is in phase 3 clinical development at Eli Lilly and Company for blood glucose management in adults with type 2 diabetes, chronic weight management, and obesity-related heart failure with preserved ejection fraction. In addition, Tirzepatide is being studied as a potential treatment for non-alcoholic steatohepatitis (NASH). The molecule comprises a 39 amino acid peptide backbone and a side chain at residue 20. Of the 39 amino acids, 37 are naturally occurring (or coded), while two are noncoded aminoisobutyric acid residues at positions 2 and 13[1].

Tirzepatide 준비 용품 및 원자재

원자재

준비 용품

Tirzepatide 공급 업체

공급자	전화	이메일	국가	제품 수	이점
Shanghai Longyu Biotechnology Co., Ltd.	+8615821988213	info@longyupharma.com	China	2531	58
Hubei Yuanao Technology CO Ltd	+86-15377628618 +86-15377628618	info@yuanaotech.com	China	6	58
HangZhou RunYan Pharma Technology Co.,LTD.	+86-88660901 +86-18112526015	sales@runyanpharma.com	China	326	58
Shanghai Getian Industrial Co., LTD	+86-15373193816 +86-15373193816	mike@ge-tian.com	China	272	58
Hebei Lingding Biotechnology Co., Ltd.	+86-18031140164 +86-19933155420	erin@hbldbiotech.com	China	878	58
Henan Tengmao Chemical Technology Co. LTD	+8615238638457	salesvip2@hntmhg.com	China	415	58
Hebei Mojin Biotechnology Co., Ltd	+8613288715578	sales@hbmojin.com	China	12456	58
Wuhan Cell Pharmaceutical Co., Ltd	+86-13129979210 +86-13129979210	sales@cellwh.com	China	376	58
Xiamen Wonderful Bio Technology Co., Ltd.	+8613043004613	Sara@xmwonderfulbio.com	China	305	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58

Tirzepatide 관련 검색: